Introduction

Non-Alcoholic Fatty Liver Disease (NAFLD) has emerged as one of the most common chronic liver diseases worldwide and is increasingly becoming a major public health concern in India. It is often called a “silent epidemic” because many patients remain asymptomatic for years until significant liver damage has already occurred.

NAFLD refers to excessive accumulation of fat in the liver in individuals who consume little or no alcohol. The disease spectrum ranges from simple fatty liver (steatosis) to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even hepatocellular carcinoma.

With rising obesity, diabetes mellitus, sedentary lifestyle, and unhealthy dietary habits, NAFLD prevalence is rapidly increasing among adults as well as younger individuals.

Understanding NAFLD



NAFLD is diagnosed when hepatic fat accumulation exceeds 5% of liver weight in the absence of significant alcohol intake or other secondary causes of fatty liver disease.

The disease is broadly classified into:

1. Simple Fatty Liver (Non-Alcoholic Fatty Liver)

  • Fat deposition in liver cells without inflammation
  • Usually benign and reversible

2. Non-Alcoholic Steatohepatitis (NASH)

  • Fat accumulation associated with inflammation and hepatocyte injury
  • Can progress to fibrosis and cirrhosis

3. Advanced Liver Disease

  • Fibrosis
  • Cirrhosis
  • Liver failure
  • Hepatocellular carcinoma

Epidemiology

NAFLD affects nearly 25–30% of the global population. In India, prevalence is increasing rapidly due to urbanization and metabolic syndrome.

High-risk groups include:

  • Obese individuals
  • Patients with Type 2 Diabetes Mellitus
  • Dyslipidemia
  • Hypertension
  • Sedentary lifestyle
  • Polycystic ovarian syndrome (PCOS)

Alarmingly, NAFLD is now increasingly seen in non-obese individuals (“lean NAFLD”), particularly in Asian populations.

Pathophysiology



The pathogenesis of NAFLD is multifactorial and closely linked to insulin resistance.

Major mechanisms include:

  • Increased free fatty acid influx into liver
  • Hepatic fat accumulation
  • Oxidative stress
  • Mitochondrial dysfunction
  • Inflammatory cytokine release
  • Gut microbiota alterations

Insulin resistance plays a central role and contributes to both hepatic steatosis and progression to NASH.

Clinical Features

Most patients remain asymptomatic for long periods.

When symptoms occur, they may include:

  • Fatigue
  • Malaise
  • Right upper abdominal discomfort
  • Hepatomegaly

Advanced disease may present with:

  • Jaundice
  • Ascites
  • Pedal edema
  • Gastrointestinal bleeding
  • Features of portal hypertension

Risk Factors

Metabolic Factors

  • Obesity
  • Central adiposity
  • Type 2 diabetes mellitus
  • Hypertriglyceridemia
  • Hypertension

Lifestyle Factors

  • Sedentary behavior
  • High-calorie diet
  • Excess fructose intake
  • Processed foods

Other Associated Conditions

  • Hypothyroidism
  • Obstructive sleep apnea
  • PCOS
  • Chronic kidney disease

Diagnosis



Laboratory Findings

  • Elevated ALT and AST
  • Mild increase in GGT
  • Dyslipidemia
  • Elevated fasting glucose/HbA1c

However, liver enzymes may be normal despite significant disease.

Imaging

  • Ultrasonography: First-line investigation
  • FibroScan: Assesses fibrosis
  • CT/MRI: Quantifies liver fat

Liver Biopsy

Gold standard for diagnosing NASH and staging fibrosis, though not routinely required in all patients.

Complications

If untreated, NAFLD can progress to serious complications:

  • Liver fibrosis
  • Cirrhosis
  • Hepatocellular carcinoma
  • Liver failure

Importantly, cardiovascular disease remains the leading cause of mortality in NAFLD patients.

Management

Lifestyle Modification: The Cornerstone



Weight Reduction

  • 7–10% weight loss significantly improves liver histology
  • Gradual and sustained weight loss is preferred

Dietary Measures

Recommended:

  • Mediterranean-style diet
  • High-fiber foods
  • Fruits and vegetables
  • Whole grains

Avoid:

  • Sugary beverages
  • Refined carbohydrates
  • Processed foods
  • Saturated fats

Physical Activity

  • At least 150 minutes/week of moderate exercise
  • Combination of aerobic and resistance training

Pharmacological Therapy

Currently, no universally approved drug exists specifically for NAFLD, but selected therapies may help:

  • Vitamin E in non-diabetic NASH patients
  • Pioglitazone in selected patients
  • GLP-1 receptor agonists for obesity and diabetes
  • Statins for dyslipidemia

Management should also target associated metabolic disorders.

Prevention

Preventive strategies include:

  • Maintaining healthy body weight
  • Regular exercise
  • Early diabetes control
  • Balanced diet
  • Avoidance of alcohol excess
  • Regular health screening

Early detection is crucial because NAFLD is largely reversible in its initial stages.

NAFLD in India: Emerging Concerns



India faces a dual burden of malnutrition and metabolic diseases. Rapid urbanization, changing food habits, and reduced physical activity have contributed significantly to rising NAFLD prevalence.

Increasing incidence among young adults and adolescents is particularly concerning and highlights the need for public awareness and preventive healthcare strategies.

Conclusion

NAFLD represents a growing silent epidemic closely linked with modern lifestyle disorders. Because patients often remain asymptomatic until advanced disease develops, early identification and timely intervention are essential.

Lifestyle modification remains the most effective therapeutic strategy. Physicians must actively screen high-risk individuals, educate patients regarding healthy lifestyle habits, and manage associated metabolic conditions comprehensively.

With increasing prevalence across all age groups, NAFLD is no longer merely a liver disease—it is a major metabolic health challenge requiring multidisciplinary attention.


Dr. Prakash Agarwal

MBBS, FIM (Internal Medicine)

Consultant Physician